Phuong Vu

Phuong Vu

biostatistician, data enthusiast, gamer

Publications

For the most updated list of publications, follow me on either Google Scholar, PubMed, or ORCID

Applied work in cystic fibrosis

  1. Green N, Vu PT, Xie J, …, & Lusman SS (2026). Impact of Elexacaftor/Tezacaftor/Ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE Pediatric Substudy. Journal of Cystic Fibrosis, 25(3):489-494. [link]
  2. Sagel S, Vu PT, Heltshe S, …, & Felix Ratjen (2025). Elexacaftor/Tezacaftor/Ivacaftor is Associated with a Long-Term Reduction in Use of Chronic Respiratory Therapies in Cystic Fibrosis. Journal of Cystic Fibrosis, 25(3):450-456. [link]
  3. Pittman JE, Morgan S, McCreary M, Vu PT, …, & Ratjen F (2025). Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6 to 11-Year-Olds with Cystic Fibrosis. Annals of the American Thoracic Society, 22(11), 1696-1708. [link]
  4. Rayas MS, Mbogo B, Kelly A, Vu PT, Magaret A, & Daley T (2025). Association of Race and Ethnicity with the Development of Cystic Fibrosis-Related Diabetes. Journal of Cystic Fibrosis, 24(2), 263-270. [link]
  5. Lee MJ, Sathe M, Moshiree B, Vu PT, …, & Freeman AJ (2024). Establishing Minimal Clinically Important Difference (MCID) for the GALAXY Study. Journal of Cystic Fibrosis, 23(5), 991-999. [link]
  6. Merjaneh L, Sidhaye AR, Vu PT, …, & Rosenfeld M (2023). Role of Hyperglycemia in Cystic Fibrosis Pulmonary Exacerbations. Journal of Cystic Fibrosis, 22(5):868-874. [link]
  7. Moshiree B, Freeman AJ, Vu PT, …, & Sathe M (2022). Multi-center Prospective Study of Gastrointestinal Symptom Prevalence and Severity in Cystic Fibrosis: The GALAXY Results. Journal of Cystic Fibrosis, 22(2):266-274. [link]
  8. Schwarzenberg SJ, Vu PT, Skalland M, …, & Freedman S for the PROMISE Study Group (2022). Elexacaftor/Tezacaftor/Ivacaftor and Gastrointestinal Outcomes in Cystic Fibrosis: Report of PROMISE-GI. Journal of Cystic Fibrosis, 22(2):282-289. [link]
  9. Jain R, Magaret A, Vu PT, …, & Taylor-Cousar JL (2022). Prospectively Evaluating Maternal and Fetal Outcomes in the Era of CFTR Modulators: the MAYFLOWERS Observational Clinical Trial Study Design. BMJ Open Respiratory Research, 9(1), e001289. [link]
  10. Sathe M, Moshiree B, Vu PT, …, & Freeman JA (2021). Utilization of Electronic Patient-Reported Outcome Measures in Cystic Fibrosis Research: Application of the GALAXY Study. Journal of Cystic Fibrosis, 20(4):605-611 [link]

Methodological work in spatial statistics

  1. Vu PT, Szpiro AA, & Simon N (2022). Spatial Matrix Completion for Spatially-Misaligned and Multivariate Air Pollution Data. Environmetrics, 33(4), e2713. [link]
  2. Vu PT, Larson TV, & Szpiro AA (2020). Probabilistic Predictive Principal Component Analysis for Spatially Misaligned and High‐Dimensional Air Pollution Data with Missing Observations. Environmetrics, 31(4), e2614. [link]
  3. Vu PT (2019). Dimension Reduction for Spatially-Misaligned and Multi-Pollutant Data with Missing Observations. [doctoral dissertation]

Applied work in pediatric and neonatal research

  1. German KR, Vu PT, Comstock BA, …, & Juul SE for the PENUT Consortium (2021). Enteral Iron Supplementation in Extremely Preterm Infants and Its Positive Correlation with Neurodevelopment; Post Hoc Analysis of the PENUT Randomized Controlled Trial. The Journal of Pediatrics, 238:102-109.e8. [link]
  2. German KR, Vu PT, Neches S, and Juul SE (2021). Comparison of Markers of Iron Sufficiency Status and Neurodevelopmental Outcomes. Early Human Development, 158, 105395. [link]
  3. Vu PT, Ohls RK, Mayock DE, …, & Juul SE, for the PENUT Consortium (2021). Transfusions and Neurodevelopmental Outcomes in Extremely Low Gestation Neonates Enrolled in the Preterm Erythropoietin Neuroprotection (PENUT) Trial. Pediatric Research, 1-8. [link]
  4. Juul SE, Vu PT, Comstock BA, …, & Heagerty PJ, for the PENUT Consortium (2020). The Effect of High Dose Erythropoietin on Blood Transfusions in Extremely Low Gestational Age Neonates: A Randomized Clinical Trial. JAMA Pediatrics, 174(10), 933-943. [link]
  5. Juul SE, Comstock BA, Wadhawan R, …, Vu PT, …, & Heagerty PJ, for the PENUT Consortium (2020). A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. New England Journal of Medicine, 382(3), 233-243. [link]
  6. German KR, Vu PT, Irvine J, & Juul SE (2019). Trends in Reticulocyte Hemoglobin Equivalent Values in Critically Ill Neonates, Stratified by Gestational Age. Journal of Perinatology, 39(9), 1268-1274. [link]
  7. German KR, Vu PT, Grelli KN, Denton C, Lee G, & Juul SE (2018). Zinc Protoporphyrin-to-heme Ratio and Ferritin as Measures of Iron Sufficiency in the Neonatal Intensive Care Unit. The Journal of Pediatrics, 194, 47-53. [link]

Other applied work

  1. Wood TR, Vu PT, Comstock BA, …, & Juul SE (2021). Cytokine and Chemokine Responses to Injury and Treatment in a Nonhuman Primate Model of Hypoxic-Ischemic Encephalopathy Treated with Hypothermia and Erythropoietin. Journal of Cerebral Blood Flow and Metabolism, 41(8):2054-2066. [link]
  2. Lenhart JG, Vu PT, Quackenbush K, LaPorte A, & Smith J (2020). The Efficacy of a Compounded Micronutrient Supplement on the Incidence, Duration, and Severity of the Common Cold: A Pilot Randomized, Double-blinded Placebo-Controlled Trial. PLoS ONE, 15(8), e0237491. [link]
  3. DeVine AC, Vu PT, Yost MG, Seto E, & Busch Isaksen TM (2017). A Geographical Analysis of Emergency Medical Service Calls and Extreme Heat in King County, WA (2007-2012). International Journal of Environmental Research and Public Health, 14.8, 937. [link]
  4. Matsen FA, Russ SM, Vu PT, Hsu JE, Lucas RM, & Comstock BA (2016). What Factors are Predictive of Patient-reported Outcomes? A Prospective Study of 337 Shoulder Arthroplasties. Clinical Orthopaedics and Related Research, 474(11), 2496-2510. [link]